Post-Budget Summit

2025 BPD Annual Conference

This annual event will focus on the critical issues impacting the life sciences sector and all stakeholders with an interest in access to health technologies.

19 May 2025

Sydney, Australia
The Ivy Ballroom

The half-day summit will discuss the implications of the Labor federal government's first Budget and the progress of other policy initiatives, including the National Medicines Policy and health technology assessment reviews.

About The Event.

The annual event occurs at a critical time with an expected federal election and the implementation of major policy initiatives, including the Health Technology Assessment Review.

An agenda for people interested in what stakeholders with an interest in access to health technologies should expected in the lead up to the election

The program will be built to provide an engaging, informed and wide-ranging discussion on these and other related issues with the goal to ensure an open dialogue involving patients.

Complimentary registration will be available for patients and their representatives - email contact@dailydispatch.com.au for more information.

About

+200

8

Participants

Sessions

Speakers

Anchor 1

Location

Program

8.30 am - 9.00 am Conference venue opens

9.00am - 9.10am Conference welcome

9.10am - 9.50am What matters to patients?

Jonathan Smithers, CEO, Arthritis Australia

Tamara Dawson, Founder and CEO, Melanoma & Skin Cancer Advocacy Network

Petrina Fraccaro, CEO and Managing Director, Cystic Fibrosis Queensland and Trusted Care

9.50am - 10.30am 2025 Federal Election wrap-up

Jody Fassina, Insight Strategy

10.30am - 11.00am Break

11.00am - 11.45am The opportunities and vulnerabilities for Australia’s life sciences sector against a backdrop of global uncertainty

Rebekah Cassidy, CEO, AusBiotech

Kylie Sproston, CEO, Bellberry

11.45am - 12.30pm What’s the story with nuclear medicine in Australia

Simone Leyden AM, Senior Director Global Patient Advocacy and Government Affairs, Telix

Michelle Gregory, Radioligand Therapies Lead, Novartis Australia and New Zealand

12.30pm - 1.30pm Break

1.30pm - 2.15pm Medicines Australia - future vision and strategy

Sue MacLeman, Chair, Medicines Australia

2.15pm - 3.00pm The diabetes and weight-loss conundrum

Paul Davies, Director, Government Affairs Australia and NZ, Abbott

Felicity McNeill PSM, Chair, Better Access Australia

3.00pm - 3.30pm Break

3.30pm - 4.15pm HTA Review Implementation

Liz de Somer, CEO, Medicines Australia

4.15pm - 5.00pm The case for innovation

Stuart Englund, Writer and Industy Executive

5.00pm - 6.00pm Reception